An Open-Label Extension Study to Assess the Safety of GSK1605786A in Subjects With Crohn's Disease.

Trial Profile

An Open-Label Extension Study to Assess the Safety of GSK1605786A in Subjects With Crohn's Disease.

Discontinued
Phase of Trial: Phase III

Latest Information Update: 19 Sep 2017

At a glance

  • Drugs Vercirnon (Primary)
  • Indications Crohn's disease
  • Focus Adverse reactions
  • Acronyms SHIELD-3
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 10 Jan 2014 Status changed from suspended to discontinued according to ClinicalTrials.gov record.
    • 23 Aug 2013 Status changed from recruiting to suspended, according to a GlaxoSmithKline media release. New recruitment and dosing has been suspended pending further review.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top